ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,303.27
0.12%
Dow Jones
40,003.59
0.34%
US Dollar vs MXN
16.6086
0.00%
Brent Oil
83.76
0.00%
Bitcoin
67,243.21
0.24%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. PaxMedica Inc (PXMD)

  7. PaxMedica Inc (PXMD) Noticias

PXMD

PaxMedica (PXMD)

PaxMedica Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:PXMD
FechaHoraFuenteTítuloSímboloCompañía
15/05/202407:30GlobeNewswire Inc.PaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101NASDAQ:PXMDPaxMedica Inc
07/05/202407:30GlobeNewswire Inc.PaxMedica Provides Company Update and Continues to Advance PAX-101 Regulatory StrategyNASDAQ:PXMDPaxMedica Inc
26/04/202407:30GlobeNewswire Inc.PaxMedica's CEO and Malawi Health Official Discuss Urgent Medical Crisis in Bell2Bell PodcastNASDAQ:PXMDPaxMedica Inc
23/04/202407:30GlobeNewswire Inc.PaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101NASDAQ:PXMDPaxMedica Inc
16/04/202415:30GlobeNewswire Inc.PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping SicknessNASDAQ:PXMDPaxMedica Inc
11/04/202415:30GlobeNewswire Inc.PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA SubmissionNASDAQ:PXMDPaxMedica Inc
13/03/202407:20GlobeNewswire Inc.PaxMedica Updated Company Presentation Highlighting Innovations in Autism Spectrum Disorder TreatmentsNASDAQ:PXMDPaxMedica Inc
11/03/202415:45Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:PXMDPaxMedica Inc
23/02/202416:09Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PXMDPaxMedica Inc
13/02/202419:11Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:PXMDPaxMedica Inc
29/01/202416:20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PXMDPaxMedica Inc
29/11/202315:33Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:PXMDPaxMedica Inc
21/11/202307:51Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:PXMDPaxMedica Inc
20/11/202323:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PXMDPaxMedica Inc
17/11/202307:00GlobeNewswire Inc.PaxMedica Inc. Featured in Syndicated Broadcast Highlighting FDA Type-B Meeting to Review PAX-101 Pivotal Trial DataNASDAQ:PXMDPaxMedica Inc
16/11/202315:27Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:PXMDPaxMedica Inc
09/11/202307:00GlobeNewswire Inc.PaxMedica's Chief Medical Officer Discusses FDA Meeting Highlights on The Bell2Bell PodcastNASDAQ:PXMDPaxMedica Inc
09/11/202305:02Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:PXMDPaxMedica Inc
02/11/202307:30GlobeNewswire Inc.PaxMedica Engages Bourne Partners to Explore Future Monetization of Potential Priority Review Voucher (PRV)NASDAQ:PXMDPaxMedica Inc
31/10/202307:00GlobeNewswire Inc.PaxMedica Acquires Suramin Research Assets from Rediscovery Life Sciences to Accelerate NDA Submission for PAX-101NASDAQ:PXMDPaxMedica Inc
30/10/202310:30GlobeNewswire Inc.PaxMedica Announces 1-for-17 Reverse Stock SplitNASDAQ:PXMDPaxMedica Inc
26/10/202312:51GlobeNewswire Inc.PaxMedica's Research on Low Dose Suramin for Autism Spectrum Disorder Accepted for PublicationNASDAQ:PXMDPaxMedica Inc
18/10/202309:10GlobeNewswire Inc.The Bell2Bell Podcast featuring Howard Weisman, CEO and Buzz Woods of PaxMedica, Inc. (Nasdaq: PXMD)NASDAQ:PXMDPaxMedica Inc
11/09/202315:05Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:PXMDPaxMedica Inc
01/09/202315:33Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:PXMDPaxMedica Inc
30/08/202315:26Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PXMDPaxMedica Inc
30/08/202307:00GlobeNewswire Inc.PaxMedica to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:PXMDPaxMedica Inc
16/08/202307:30GlobeNewswire Inc.PaxMedica Appoints David Hough M.D. as Chief Medical OfficerNASDAQ:PXMDPaxMedica Inc
09/08/202316:01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PXMDPaxMedica Inc
09/08/202315:15GlobeNewswire Inc.PaxMedica, Inc. Announces Second Quarter 2023 Financial Results and Business UpdateNASDAQ:PXMDPaxMedica Inc
 Showing the most relevant articles for your search:NASDAQ:PXMD

Su Consulta Reciente

BIT
C00148
Commerzbank
TSXV
DLV
DV Resources Ltd.
LSE
17GR
Westpac 42
BIT
UC7V31
Unicredit Bank
NYSE
PBC
Prospect Capital
USOTC
LIGA
LIG Assets (PK)
BOV
T1SS34M
Tenaris
NASDAQ
METX
BTC Digital
LSE
AMLN
Aston Martin Np
TSXV
TUK
Tuktu Resources
TSX
CTX
Crescita Therapeutics
KUCN
MYRIAUSDT
Myria
LSE
PAQB
BINA
WAVESETH
Waves
USOTC
NHIQ
NantHealth (PK)
NYSE
KOP
Koppers
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados